Fresenius buys Dabur's Indian oncology business

Fresenius is to acquire India's Dabur Pharma for $219 million giving it access to a portfolio of cancer treatment drugs and a supply of raw materials.

IndiaÆs Dabur Group has sold its 73.3% controlling interest in Dabur Pharma to Fresenius Kabi for Ç139 million $219 million.

Dabur Pharma is the residual pharmaceuticals business of Dabur Group. The largest business of the group, which is owned by the Delhi-based Burman family, is Dabur India. Dabur India has been operating since 1884 and is today a $250 million company focused on healthcare, personal care and food products. Its brands are especially well respected in the ayurvedic category,...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: dabur pharma | dabur | fresenius

Print Edition

FinanceAsia Print Edition